Clinical Trials Logo

Microhaemorrhage clinical trials

View clinical trials related to Microhaemorrhage.

Filter by:
  • None
  • Page 1

NCT ID: NCT03243175 Recruiting - Atrial Fibrillation Clinical Trials

Avoiding Anticoagulation After IntraCerebral Haemorrhage

A3ICH
Start date: January 24, 2019
Phase: Phase 3
Study type: Interventional

Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist (called direct OAC) - can be used for patients with AF after an intracerebral haemorrhage. Roughly 30% of adults with ICH have AF but in 2017 it remains unclear whether they should start oral anticoagulant drugs, be treated with left atrial appendage closure (LAAC) or avoid anticoagulation and LAAC.

NCT ID: NCT03153150 Completed - Atrial Fibrillation Clinical Trials

Start or STop Anticoagulants Randomised Trial (SoSTART)

SoSTART
Start date: March 28, 2018
Phase: Phase 3
Study type: Interventional

Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation (OAC) result in a beneficial net reduction of all serious vascular events compared with not starting OAC? Trial design: Investigator-led, multicentre, randomised, open, assessor-masked, parallel group, clinical trial of investigational medicinal product (CTIMP) prescribing strategies. Investigators plan for a pilot phase, followed by a safety phase.